Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A study looking at how capecitabine works in people with stomach cancer after having their stomach removed
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is to find out how capecitabine works in people with stomach cancer who have had all of their stomach removed (total gastrectomy).
Capecitabine is a tablet. For it to work properly, the body must be able to take it in. This happens in the gut.
The aim of this study is to find out how much capecitabine is absorbed into the body of people who have had all of their stomach removed.
Who can enter
You can enter this trial if you
- Have the most common type of stomach cancer (adenocarcinoma)
- Are having surgery to remove all of your stomach (total gastrectomy)
- Have satisfactory blood test results
- Are well enough to be up and about for at least half the day (performance status 0, 1, 2)
- Are willing to use reliable contraception, for 4 weeks before and 6 weeks after the study, if there is a chance that you or your partner could become pregnant
- Are at least 18 years old
You cannot enter this trial if you
- Have stomach cancer that has spread to other body organs or other parts of the body (stage 4)
- Have a build up of fluid in your tummy area (abdomen) that is caused by your cancer - doctors call this malignant ascites
- Have problems taking tablets
- Have a serious heart disease
- Are having any chemotherapy drugs other than ECX
- Have had serious side effects from chemotherapy drugs similar to capecitabine like 5 fluorouracil (5FU)
- Are known to be HIV, hepatitis B or hepatitis C positive
- Have another medical problem that could affect you taking part
- Are pregnant or breastfeeding
This is a phase 4 study. It will recruit 12 people at 2 hospitals in the UK. Everyone taking part will have chemotherapy before and after having their stomach removed. The chemotherapy is a combination of epirubicin, cisplatin and capecitabine (ECX).
You have epirubicin and cisplatin as a drip into a vein (intravenous injection) every 3 weeks.
Capecitabine is a tablet you take at home; starting on the same day you have the epirubicin and cisplatin. You take the tablets twice a day everyday for 3 weeks.
Each 3 weeks is called a cycle of treatment.
After 3 cycles of treatment, you have surgery to remove your stomach (total gastrectomy).
After surgery you see the doctor to discuss whether you should continue to have chemotherapy.
You see the doctor and have some tests before taking part in this trial. These tests include
- Physical examination
- Heart trace (
- Urine test
- Blood test
- CT scan
- Chest X-ray (if the CT scan does not include the chest)
Before cycles 2 and 3 you see the doctor and have blood tests.
Before surgery you see the doctor and have a CT scan of your tummy (abdomen) and chest. Or you may have a CT scan of the abdomen and a chest X-ray.
You start having chemotherapy again within 10 weeks of having surgery. Before starting chemotherapy, you see the doctor and have the following tests
- Physical examination
- Heart trace (ECG)
- Blood tests
Before cycles 5 and 6 you have a blood test and urine test.
You see the doctor 1 month after finishing chemotherapy.
Al treatments have side effects the most common side effects of epirubicin, cisplatin and capecitabine (ECX) are
- A drop in blood cells causing an increased risk of infection, bleeding and bruising
- Sore mouth and mouth ulcers
- Soreness, redness and peeling of the skin on the palms and soles of the feet (palmar-plantar syndrome)
- Feeling or being sick
- Changes in taste
- Hair loss
- Tiredness (fatigue)
- Loss of appetite
How to join a clinical trial
Prof Duncan Jodrell
Cambridge University Hospitals NHS Foundation Trust
Experimental Cancer Medicine Centre (ECMC)